# Bendamustine Combined With Rituximab for Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

> **NCT00831597** · PHASE2 · COMPLETED · sponsor: **Pharmatech** · enrollment: 61 (actual)

## Conditions studied

- Diffuse Large B-Cell Lymphoma

## Interventions

- **DRUG:** bendamustine
- **DRUG:** rituximab

## Key facts

- **NCT ID:** NCT00831597
- **Lead sponsor:** Pharmatech
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-11
- **Primary completion:** 2013-08
- **Final completion:** 2013-09
- **Target enrollment:** 61 (ACTUAL)
- **Last updated:** 2016-04-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00831597

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00831597, "Bendamustine Combined With Rituximab for Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma". Retrieved via AI Analytics 2026-07-18 from https://api.ai-analytics.org/clinical/NCT00831597. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*